The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Open accessAbstract
Unprecedented advances in our understanding of the pathobiology, prognostication, and therapeutic options in mantle cell lymphoma (MCL) have taken place in the last few years. Heterogeneity in the clinical course of MCL—indolent vs aggressive—is further delineated by a correlation with the mutational status of the variable region of immunoglobulin heavy chain, methylation status, and SOX‐11 expression. Cyclin‐D1 negative MCL, in situ MCL neoplasia, and impact of the karyotype on prognosis are distinguished. Apart from Ki‐67% and morphology pattern (classic vs blastoid/pleomorphic), the proliferation gene signature has helped to further refine prognostication. Studies focusing on mutational dynamics and clonal evolution on Bruton's tyrosine kinase (BTK) inhibitors (ibrutinib, acalabrutinib) and/or Bcl2 antagonists (venetoclax) have further clarified the prognostic impact of somatic mutations in TP53, BIRC3, CDKN2A, MAP3K14, NOTCH2, NSD2, and SMARCA4 genes. In therapy, long‐term follow‐up on chemo‐immunotherapy studies has demonstrated durable remissions in some patients; however, long‐term toxicities, especially from second cancers, are a serious concern with chemotherapy. The therapeutic options in MCL are constantly evolving, with dramatic responses from nonchemotherapeutic agents (ibrutinib, acalabrutinib, and venetoclax). Chimeric antigen receptor therapy and combinations of nonchemotherapeutic agents are actively being studied and our focus is shifting toward making the treatment of MCL chemotherapy‐free. Still, MCL remains incurable. The following aspects of MCL continue to pose a challenge: disease transformation, role of the cytokine‐microenvironmental milieu, incorporation of positron emission tomography‐computerized tomography imaging, minimal residual disease in the prognosis, circulating tumor DNA testing for clonal evolution, predicting resistance to BTK inhibitors, and optimal management of patients who progress on BTK/Bcl2 inhibitors. Next‐generation clinical trials should incorporate nonchemotherapeutic agents and personalize the treatment based upon the genomic profile of individual patient. Recent advances in the field of MCL are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306220 · Cited by 1,685
Self-citationHonigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
2016 US lymphoid malignancy statistics by World Health Organization subtypes
Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A., & Flowers, C. R. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21357 · Cited by 1,125
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Hoster, E., Dreyling, M., Klapper, W., Gisselbrecht, C., van Hoof, A., Kluin-Nelemans, H. C., Pfreundschuh, M., Reiser, M., Metzner, B., Einsele, H., et al. (2008) · Blood · doi:10.1182/blood-2007-06-095331 · Cited by 984
Sant, M., Allemani, C., Tereanu, C., De Angelis, R., Capocaccia, R., Visser, O., Marcos-Gragera, R., Maynadié, M., Simonetti, A., Lutz, J.-M., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282632 · Cited by 977
Davids, M. S., Roberts, A. W., Seymour, J. F., Pagel, J. M., Kahl, B. S., Wierda, W. G., Puvvada, S., Kipps, T. J., Anderson, M. A., Salem, A. H., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4320 · Cited by 748
Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9665 · Cited by 704
Smith, A., Howell, D., Patmore, R., Jack, A., & Roman, E. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.450 · Cited by 692
Flinn, I. W., van der Jagt, R., Kahl, B. S., Wood, P., Hawkins, T. E., MacDonald, D., Hertzberg, M., Kwan, Y.-L., Simpson, D., Craig, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-531327 · Cited by 643
Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
Geisler, C. H., Kolstad, A., Laurell, A., Andersen, N. S., Pedersen, L. B., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A. M., et al. (2008) · Blood · doi:10.1182/blood-2008-03-147025 · Cited by 622
Romaguera, J. E., Fayad, L., Rodriguez, M. A., Broglio, K. R., Hagemeister, F. B., Pro, B., McLaughlin, P., Younes, A., Samaniego, F., Goy, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.1825 · Cited by 557
Self-citationLandscape of somatic mutations and clonal evolution in mantle cell lymphoma
Beà, S., Valdés-Mas, R., Navarro, A., Salaverria, I., Martín-Garcia, D., Jares, P., Giné, E., Pinyol, M., Royo, C., Nadeu, F., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314608110 · Cited by 513
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.012 · Cited by 508
Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J., Lamy, T., Morschhauser, F., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33108-2 · Cited by 453 · cited 1×
“Acalabrutinib was studied in a multicenter phase II trial including 124 patients with relapsed MCL who had a median of two lines of prior therapy.(99) After a median follow up of 15.”
BackgroundAutoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype
Smedby, K. E., Hjalgrim, H., Askling, J., Chang, E. T., Gregersen, H., Porwit-MacDonald, A., Sundström, C., Åkerman, M., Melbye, M., Glimelius, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj004 · Cited by 439
Blombery, P., Anderson, M. A., Gong, J.-N., Thijssen, R., Birkinshaw, R. W., Thompson, E. R., Teh, C. E., Nguyen, T., Xu, Z., Flensburg, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1119 · Cited by 434
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Tam, C. S., Anderson, M. A., Pott, C., Agarwal, R., Handunnetti, S., Hicks, R. J., Burbury, K., Turner, G., Di Iulio, J., Bressel, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1715519 · Cited by 433
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
Le Gouill, S., Thieblemont, C., Oberic, L., Moreau, A., Bouabdallah, K., Dartigeas, C., Damaj, G., Gastinne, T., Ribrag, V., Feugier, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701769 · Cited by 416
Wang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635326 · Cited by 410
Self-citationIbrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
Grommes, C., Pastore, A., Palaskas, N., Tang, S. S., Campos, C., Schartz, D., Codega, P., Nichol, D., Clark, O., Hsieh, W.-Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0613 · Cited by 409
Eskelund, C. W., Dahl, C., Hansen, J. W., Westman, M., Kolstad, A., Pedersen, L. B., Montano-Almendras, C. P., Husby, S., Freiburghaus, C., Ek, S., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779736 · Cited by 407
McMullen, J. R., Boey, E. J. H., Ooi, J. Y. Y., Seymour, J. F., Keating, M. J., & Tam, C. S. (2014) · Blood · doi:10.1182/blood-2014-10-604272 · Cited by 403
Hermine, O., Hoster, E., Walewski, J., Bosly, A., Stilgenbauer, S., Thieblemont, C., Szymczyk, M., Bouabdallah, R., Kneba, M., Hallek, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00739-x · Cited by 400
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Osmanov, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412096 · Cited by 386
Molecular pathogenesis of mantle cell lymphoma
Jares, P., Colomer, D., & Campo, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61272 · Cited by 382
Barf, T., Covey, T., Izumi, R., van de Kar, B., Gulrajani, M., van Lith, B., van Hoek, M., de Zwart, E., Mittag, D., Demont, D., et al. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.242909 · Cited by 380
Goy, A., Sinha, R., Williams, M. E., Kalayoglu Besisik, S., Drach, J., Ramchandren, R., Zhang, L., Cicero, S., Fu, T., & Witzig, T. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2835 · Cited by 349
Fu, K. (2005) · Blood · doi:10.1182/blood-2005-04-1753 · Cited by 346
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Martin, P., Chadburn, A., Christos, P., Weil, K., Furman, R. R., Ruan, J., Elstrom, R., Niesvizky, R., Ely, S., DiLiberto, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6121 · Cited by 339
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
Kridel, R., Meissner, B., Rogic, S., Boyle, M., Telenius, A., Woolcock, B., Gunawardana, J., Jenkins, C., Cochrane, C., Ben-Neriah, S., et al. (2012) · Blood · doi:10.1182/blood-2011-11-391474 · Cited by 338
Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn656 · Cited by 336
Rahal, R., Frick, M., Romero, R., Korn, J. M., Kridel, R., Chun Chan, F., Meissner, B., Bhang, H.-E., Ruddy, D., Kauffmann, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3435 · Cited by 334
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Levade, M., David, E., Garcia, C., Laurent, P.-A., Cadot, S., Michallet, A.-S., Bordet, J.-C., Tam, C., Sié, P., Ysebaert, L., et al. (2014) · Blood · doi:10.1182/blood-2014-06-583294 · Cited by 321
Wang, M., Fayad, L., Wagner-Bartak, N., Zhang, L., Hagemeister, F., Neelapu, S. S., Samaniego, F., McLaughlin, P., Fanale, M., Younes, A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70200-0 · Cited by 297
Self-citationPostibrutinib outcomes in patients with mantle cell lymphoma
Martin, P., Maddocks, K., Leonard, J. P., Ruan, J., Goy, A., Wagner-Johnston, N., Rule, S., Advani, R., Iberri, D., Phillips, T., et al. (2016) · Blood · doi:10.1182/blood-2015-10-673145 · Cited by 294
Sun, J., Yang, Q., Lu, Z., He, M., Gao, L., Zhu, M., Sun, L., Wei, L., Li, M., Liu, C., et al. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcp7yltqpusdq5c · Cited by 271
Delarue, R., Haioun, C., Ribrag, V., Brice, P., Delmer, A., Tilly, H., Salles, G., Van Hoof, A., Casasnovas, O., Brousse, N., et al. (2013) · Blood · doi:10.1182/blood-2011-09-370320 · Cited by 270
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
Romaguera, J. E., Medeiros, L. J., Hagemeister, F. B., Fayad, L. E., Rodriguez, M. A., Pro, B., Younes, A., McLaughlin, P., Goy, A., Sarris, A. H., et al. (2003) · Cancer · doi:10.1002/cncr.11096 · Cited by 269
Navarro, A., Clot, G., Royo, C., Jares, P., Hadzidimitriou, A., Agathangelidis, A., Bikos, V., Darzentas, N., Papadaki, T., Salaverria, I., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1615 · Cited by 256
Wiestner, A., Tehrani, M., Chiorazzi, M., Wright, G., Gibellini, F., Nakayama, K., Liu, H., Rosenwald, A., Muller-Hermelink, H. K., Ott, G., et al. (2007) · Blood · doi:10.1182/blood-2006-08-039859 · Cited by 252
Kahl, B. S., Spurgeon, S. E., Furman, R. R., Flinn, I. W., Coutre, S. E., Brown, J. R., Benson, D. M., Byrd, J. C., Peterman, S., Cho, Y., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537555 · Cited by 252
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma
Grommes, C., Tang, S. S., Wolfe, J., Kaley, T. J., Daras, M., Pentsova, E. I., Piotrowski, A. F., Stone, J., Lin, A., Nolan, C. P., et al. (2019) · Blood · doi:10.1182/blood-2018-09-875732 · Cited by 247
Romaguera, J. E., Fayad, L. E., Feng, L., Hartig, K., Weaver, P., Rodriguez, M. A., Hagemeister, F. B., Pro, B., McLaughlin, P., Younes, A., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08228.x · Cited by 245
Self-citationLenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
Ruan, J., Martin, P., Shah, B., Schuster, S. J., Smith, S. M., Furman, R. R., Christos, P., Rodriguez, A., Svoboda, J., Lewis, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505237 · Cited by 236
Pinyol, M., Hernandez, L., Cazorla, M., Balbı́n, M., Jares, P., Fernandez, P. L., Montserrat, E., Cardesa, A., Lopez-Otı́n, C., & Campo, E. (1997) · Blood · doi:10.1182/blood.v89.1.272 · Cited by 226
Cervantes-Gomez, F., Lamothe, B., Woyach, J. A., Wierda, W. G., Keating, M. J., Balakrishnan, K., & Gandhi, V. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2809 · Cited by 222
Eskelund, C. W., Kolstad, A., Jerkeman, M., Räty, R., Laurell, A., Eloranta, S., Smedby, K. E., Husby, S., Pedersen, L. B., Andersen, N. S., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14241 · Cited by 217
Wang, M. L., Lee, H., Chuang, H., Wagner-Bartak, N., Hagemeister, F., Westin, J., Fayad, L., Samaniego, F., Turturro, F., Oki, Y., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00438-6 · Cited by 216
Self-citationMorschhauser, F. A., Cartron, G., Thieblemont, C., Solal-Céligny, P., Haioun, C., Bouabdallah, R., Feugier, P., Bouabdallah, K., Asikanius, E., Lei, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9585 · Cited by 206
Ek, S., Dictor, M., Jerkeman, M., Jirström, K., & Borrebaeck, C. A. K. (2008) · Blood · doi:10.1182/blood-2007-06-093401 · Cited by 204
Chang, B. Y., Francesco, M., De Rooij, M. F. M., Magadala, P., Steggerda, S. M., Huang, M. M., Kuil, A., Herman, S. E. M., Chang, S., Pals, S. T., et al. (2013) · Blood · doi:10.1182/blood-2013-02-482125 · Cited by 203
Agarwal, R., Chan, Y.-C., Tam, C. S., Hunter, T., Vassiliadis, D., Teh, C. E., Thijssen, R., Yeh, P., Wong, S. Q., Ftouni, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0243-z · Cited by 203
CCND2 rearrangements are the most frequent genetic events in cyclin D1− mantle cell lymphoma
Salaverria, I., Royo, C., Carvajal-Cuenca, A., Clot, G., Navarro, A., Valera, A., Song, J. Y., Woroniecka, R., Rymkiewicz, G., Klapper, W., et al. (2013) · Blood · doi:10.1182/blood-2012-08-452284 · Cited by 201
Kurtova, A. V., Tamayo, A. T., Ford, R. J., & Burger, J. A. (2009) · Blood · doi:10.1182/blood-2008-10-185827 · Cited by 199
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Herling, C. D., Abedpour, N., Weiss, J., Schmitt, A., Jachimowicz, R. D., Merkel, O., Cartolano, M., Oberbeck, S., Mayer, P., Berg, V., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03170-7 · Cited by 198
Wang, S. S., Slager, S. L., Brennan, P., Holly, E. A., De Sanjose, S., Bernstein, L., Boffetta, P., Cerhan, J. R., Maynadie, M., Spinelli, J. J., et al. (2007) · Blood · doi:10.1182/blood-2006-06-031948 · Cited by 190
Hadzidimitriou, A., Agathangelidis, A., Darzentas, N., Murray, F., Delfau-Larue, M.-H., Pedersen, L. B., Lopez, A. N., Dagklis, A., Rombout, P., Beldjord, K., et al. (2011) · Blood · doi:10.1182/blood-2011-03-343434 · Cited by 181
Vegliante, M. C., Palomero, J., Pérez‐Galán, P., Roué, G., Castellano, G., Navarro, A., Clot, G., Moros, A., Suárez-Cisneros, H., Beà, S., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438937 · Cited by 177
Bruton tyrosine kinase degradation as a therapeutic strategy for cancer
Dobrovolsky, D., Wang, E. S., Morrow, S., Leahy, C., Faust, T., Nowak, R. P., Donovan, K. A., Yang, G., Li, Z., Fischer, E. S., et al. (2019) · Blood · doi:10.1182/blood-2018-07-862953 · Cited by 169
Rule, S., Dreyling, M., Goy, A., Hess, G., Auer, R., Kahl, B., Hernández-Rivas, J.-Á., Qi, K., Deshpande, S., Parisi, L., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205229 · Cited by 169
Self-citationThe BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
Reiff, S. D., Mantel, R., Smith, L. L., Greene, J. T., Muhowski, E. M., Fabian, C. A., Goettl, V. M., Tran, M., Harrington, B. K., Rogers, K. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1409 · Cited by 165
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma
Saba, N. S., Liu, D., Herman, S. E. M., Underbayev, C., Tian, X., Behrend, D., Weniger, M. A., Skarzynski, M., Gyamfi, J., Fontan, L., et al. (2016) · Blood · doi:10.1182/blood-2015-11-681460 · Cited by 162
Robak, T., Jin, J., Pylypenko, H., Verhoef, G. E. G., Siritanaratkul, N., Drach, J. W., Raderer, M., Mayer, J., Pereira, J. C., Tumyan, G. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30685-5 · Cited by 162
Carvajal-Cuenca, A., Sua, L. F., Silva, N. M., Pittaluga, S., Royo, C., Song, J. Y., Sargent, R. L., Espinet, B., Climent, F., Jacobs, S. A., et al. (2012) · Haematologica · doi:10.3324/haematol.2011.052621 · Cited by 161
Trněný, M., Lamy, T., Walewski, J. A., Belada, D., Mayer, J., Radford, J. A., Jurczak, W. J., Morschhauser, F., Alexeeva, J., Rule, S. A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00559-8 · Cited by 156
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
Zhao, X., Lwin, T., Silva, A., Shah, B. D., Tao, J., Fang, B., Zhang, L., Fu, K., Li, J., Li, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms14920 · Cited by 154
Self-citationJerkeman, M., Eskelund, C. W., Hutchings, M., Räty, R., Wader, K. F., Laurell, A., Toldbod, H., Pedersen, L. B., Niemann, C. U., Dahl, C., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30018-8 · Cited by 154
Rule, S. A., Dreyling, M. H., Goy, A. H., Heß, G., Auer, R. L., Kahl, B. S., Cavazos, N., Liu, B., Yang, S., Clow, F., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14870 · Cited by 153
Self-citationDecoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage
Queirós, A. C., Beekman, R., Vilarrasa‐Blasi, R., Duran‐Ferrer, M., Clot, G., Merkel, A., Raineri, E., Russiñol, N., Castellano, G., Beà, S., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.014 · Cited by 150
Activity of ibrutinib in mantle cell lymphoma patients with central nervous system relapse
Bernard, S., Goldwirt, L., Amorim, S., Brice, P., Brière, J., de Kerviler, É., Mourah, S., Sauvageon, H., & Thiéblemont, C. (2015) · Blood · doi:10.1182/blood-2015-05-647834 · Cited by 149
Eyre, T. A., Walter, H. S., Iyengar, S., Follows, G., Cross, M., Fox, C. P., Hodson, A., Coats, J. T., Narat, S., Morley, N. J., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.198812 · Cited by 142
Skibola, C. F., Bracci, P. M., Nieters, A., Brooks-Wilson, A. R., de Sanjosé, S., Hughes, A. M., Cerhan, J. R., Skibola, D. R., Purdue, M. P., Kane, E. V., et al. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwp383 · Cited by 137
Visco, C., Chiappella, A., Nassi, L., Patti, C., Ferrero, S., Barbero, D., Evangelista, A., Spina, M., Molinari, A., Rigacci, L., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30185-5 · Cited by 137
Bye, A. P., Unsworth, A. J., Desborough, M., Hildyard, C., Appleby, N., Bruce, D., Kriek, N., Nock, S. H., Sage, T., Hughes, C. E., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017011999 · Cited by 134
Nordström, L., Sernbo, S., Edén, P., Grønbæk, K., Kolstad, A., Räty, R., Karjalainen, M., Geisler, C. H., Ralfkiaer, E. M., Sundström, C., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12854 · Cited by 133
Jain, P., Kanagal‐Shamanna, R., Zhang, S., Ahmed, M., Ghorab, A., Zhang, L., Ok, C. Y., Li, S., Hagemeister, F. B., Zeng, D., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15567 · Cited by 126
Self-citationFive-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma
Ruan, J., Martin, P., Christos, P. J., Cerchietti, L. C. A., Tam, W., Shah, B. D., Schuster, S. J., Rodriguez, A., Hyman, D. M., Calvo-Vidal, M. N., et al. (2018) · Blood · doi:10.1182/blood-2018-07-859769 · Cited by 124
Scott, D. W., Abrisqueta, P., Wright, G. W., Slack, G. W., Mottok, A., Villa, D. R., Jares, P., Rauert‐Wunderlich, H., Royo, C., Clot, G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7901 · Cited by 122
Puente, X. S., Jares, P., & Campo, E. (2018) · Blood · doi:10.1182/blood-2017-10-764373 · Cited by 121
Balsas, P., Palomero, J., Eguileor, Á., Rodríguez, M. L., Vegliante, M. C., Planas‐Rigol, E., Sureda-Gómez, M., Cid, M. C., Campo, E., & Amador, V. (2017) · Blood · doi:10.1182/blood-2017-04-776740 · Cited by 119
Palomero, J., Vegliante, M. C., Rodríguez, M. L., Eguileor, Á., Castellano, G., Planas‐Rigol, E., Jares, P., Ribera‐Cortada, I., Cid, M. C., Campo, E., et al. (2014) · Blood · doi:10.1182/blood-2014-04-569566 · Cited by 112
CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1− mantle cell lymphoma
Martin‐García, D., Navarro, A., Valdés‐Mas, R., Clot, G., Gutiérrez‐Abril, J., Prieto, M., Ribera‐Cortada, I., Woroniecka, R., Rymkiewicz, G., Bens, S., et al. (2018) · Blood · doi:10.1182/blood-2018-07-862151 · Cited by 111
Nagy, B., Lundán, T., Larramendy, M. L., Aalto, Y., Zhu, Y., Niini, T., Edgren, H., Ferrer, A., Vilpo, J., Elonen, E., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04121.x · Cited by 107
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
Hershkovitz‐Rokah, O., Pulver, D., Lenz, G., & Shpilberg, O. (2018) · British Journal of Haematology · doi:10.1111/bjh.15108 · Cited by 104
Rule, S. A., Jurczak, W. J., Jerkeman, M., Rusconi, C., Trněný, M., Offner, F. C., Caballero, D. M., Joao, C. M., Witzens‐Harig, M., Hess, G., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0023-2 · Cited by 103
Clot, G., Jares, P., Giné, E., Navarro, A., Royo, C., Pinyol, M., Martin‐García, D., Demajo, S., Espinet, B., Salar, A., et al. (2018) · Blood · doi:10.1182/blood-2018-03-838136 · Cited by 101
Kanagal‐Shamanna, R., Jain, P., Patel, K. P., Routbort, M., Bueso‐Ramos, C., Alhalouli, T., Khoury, J. D., Luthra, R., Ferrajoli, A., Keating, M., et al. (2019) · Cancer · doi:10.1002/cncr.31831 · Cited by 98
Self-citationSurvival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
Gerson, J. N., Handorf, E. A., Villa, D. R., Gerrie, A. S., Chapani, P., Li, S., Medeiros, L. J., Wang, M. L., Cohen, J. B., Calzada, O., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00690 · Cited by 95
Self-citationStrategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas
Pham, L. V., Huang, S., Zhang, H., Zhang, J., Bell, T., Zhou, S., Pogue, E., Ding, Z., Lam, L. T., Westin, J. R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3004 · Cited by 94
Self-citationAlbertsson‐Lindblad, A., Kolstad, A., Laurell, A., Räty, R., Grønbæk, K., Sundberg, J., Pedersen, L. B., Ralfkiaer, E. M., Karjalainen‐Lindsberg, M., Sundström, C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-704023 · Cited by 90
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Martin, P., Bartlett, N. L., Blum, K. A., Park, S. I., Maddocks, K. J., Ruan, J., Ridling, L., Dittus, C. E., Chen, Z., Huang, X., et al. (2019) · Blood · doi:10.1182/blood-2018-11-886457 · Cited by 84
Observation as the initial management strategy in patients with mantle cell lymphoma
Abrisqueta, P., Scott, D. W., Slack, G. W., Steidl, C., Mottok, A., Gascoyne, R. D., Connors, J. M., Sehn, L. H., Savage, K. J. J., Gerrie, A. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx333 · Cited by 83
O’Connor, O. A., Moskowitz, C. H., Portlock, C. S., Hamlin, P. A., Straus, D. J., Dumitrescu, O., Sarasohn, D. M. M., Gönen, M., Butos, J. N., Neylon, E., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07466.x · Cited by 82
Roué, G., López‐Guerra, M., Milpied, P. J., Pérez‐Galán, P., Villamor, N., Montserrat, E., Campo, E., & Colomer, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0388 · Cited by 82
Schraders, M., Pfundt, R., Straatman, H., Janssen, I. M., van Kessel, A. G., Schoenmakers, E., van Krieken, J. H., & Groenen, P. J. T. A. (2004) · Blood · doi:10.1182/blood-2004-07-2730 · Cited by 80
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
Mohanty, A. R., Sandoval, N., Das, M., Pillai, R. K., Chen, L., Chen, R. W., Amin, H. M., Wang, M. L., Marcucci, G., Weisenburger, D. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12434 · Cited by 80
Self-citationLiu, H., Johnson, J. L., Koval, G., Malnassy, G., Sher, D., Damon, L. E., Hsi, E. D., Bucci, D. M., Linker, C. A., Cheson, B. D., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.050203 · Cited by 78
Lee, J., Zhang, L. L., Wu, W., Guo, H., Li, Y., SUKHANOVA, M. J., Venkataraman, G., Huang, S., Zhang, H., Alikhan, M. B., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016048 · Cited by 69
Self-citationRobinson, S. P., Boumendil, A., Finel, H., Peggs, K. S., Chevallier, P., Sierra, J., Finke, J., Poiré, X., Maillard, N., Milpied, N. J., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-017-0067-3 · Cited by 64
Jain, P., Romaguera, J. E., Srour, S. A., Lee, H. J., Hagemeister, F. B., Westin, J. R., Fayad, L., Samaniego, F., Badillo, M., Zhang, L., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15411 · Cited by 64
Self-citationHarrington, B. K., Gardner, H. L., Izumi, R. E., Hamdy, A., Rothbaum, W. M., Coombes, K. R., Covey, T. M., Kaptein, A., Gulrajani, M., van Lith, B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159607 · Cited by 61
Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients
Hu, Z., Medeiros, L. J., Chen, Z., Chen, W., Li, S., Konoplev, S. N., Lu, X. Y., Pham, L. V., Young, K. H., Wang, W., et al. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000758 · Cited by 60
Hu, Z., Sun, Y. J., Schlette, E. J., Tang, G., Li, S., Xu, J., Yin, C. C., Young, K. H., Patel, K. P., Miranda, R. N., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.135 · Cited by 59
Self-citationGenomic landscape and prognostic analysis of mantle cell lymphoma
Yang, P., Zhang, W., Wang, J., Liu, Y., An, R., & Jing, H. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0022-5 · Cited by 59
Bernard, S., Danglade, D., Gardano, L., Laguillier, C., Lazarian, G., Roger, C., Thiéblemont, C., Marzec, J., Gribben, J. G., Cymbalista, F., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29326 · Cited by 57
Rudelius, M., Rosenfeldt, M. T., Leich, E., Rauert‐Wunderlich, H., Solimando, A. G., Beilhack, A., Ott, G., & Rosenwald, A. (2017) · Haematologica · doi:10.3324/haematol.2017.177162 · Cited by 57
Husby, S., Ralfkiær, U., Garde, C., Zandi, R., Ek, S., Kolstad, A., Jerkeman, M., Laurell, A., Räty, R., Pedersen, L. B., et al. (2015) · Blood · doi:10.1182/blood-2014-06-584193 · Cited by 55
SOX11 augments BCR signaling to drive MCL-like tumor development
Kuo, P.-Y., Jatiani, S., Rahman, A. H., Edwards, D., Jiang, Z., Ahr, K. F., Perumal, D., Leshchenko, V. V., Brody, J., Shaknovich, R., et al. (2018) · Blood · doi:10.1182/blood-2018-02-832535 · Cited by 54
Ming, M., Wu, W., Xie, B., SUKHANOVA, M. J., Wang, W., Kadri, S., Sharma, S., Lee, J., Shacham, S., Landesman, Y., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0789-atr · Cited by 52
Cytoplasmic cyclin D1 controls the migration and invasiveness of mantle lymphoma cells
Body, S., Esteve‐Arenys, A., Miloudi, H., Recasens-Zorzo, C., Tchakarska, G., Moros, A., Bustany, S., Vidal‐Crespo, A., Rodríguez, V., Lavigne, R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14222-1 · Cited by 50
Prognostic impact of monocyte count at presentation in mantle cell lymphoma
von Hohenstaufen, K. A., Conconi, A., de Campos, C. P., Franceschetti, S., Bertoni, F., Casaluci, G. M., Stathis, A., Ghielmini, M. E. G., Stüssi, G., Cavalli, F., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12409 · Cited by 49
Allinne, J., Pichugin, A., Iarovaia, O. V., Klibi, M., Barat, A., Zlotek-Zlotkiewicz, E., Markozashvili, D., Petrova, N. V., Camara‐Clayette, V., Ioudinkova, E. S., et al. (2014) · Blood · doi:10.1182/blood-2013-06-510511 · Cited by 49
Gressin, R., Daguindau, N., Tempescul, A., Moreau, A., Carras, S., Tchernonog, E., Schmitt, A., Houot, R., Dartigeas, C., Pignon, J. M., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.191429 · Cited by 48
Smedby, K. E. E., Sampson, J. N., Turner, J., Slager, S. L., Maynadié, M., Roman, E., Habermann, T. M., Flowers, C. R., Berndt, S. I., Bracci, P. M., et al. (2014) · JNCI Monographs · doi:10.1093/jncimonographs/lgu007 · Cited by 48
Choe, J., Yun, J. Y., Na, H. Y., Huh, J., Shin, S., Kim, H., Paik, J. H., Kim, Y. A., Nam, S. J., Jeon, Y. K., et al. (2015) · Histopathology · doi:10.1111/his.12760 · Cited by 46
Fu, S., Wang, M. L., Lairson, D. R., Li, R., Zhao, B., & Du, X. L. (2017) · Oncotarget · doi:10.18632/oncotarget.22367 · Cited by 46
Self-citationGoswami, R. S., Atenafu, E. G., Xuan, Y., Waldron, L., Reis, P. P., Sun, T., Datti, A., Xu, W., Kuruvilla, J. G., Good, D. J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3050 · Cited by 43
Navarro, A., Clot, G., Prieto, M., Royo, C., Vegliante, M. C., Amador, V., Hartmann, E., Salaverría, I., Beà, S., Martín-Subero, J. I., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3077 · Cited by 40
Smoldering mantle cell lymphoma
Ye, H., Desai, A. P., Zeng, D., Nomie, K. J., Romaguera, J. E., Ahmed, M., & Wang, M. L. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0652-8 · Cited by 38
Self-citationWang, M. L., Fayad, L., Cabanillas, F., Hagemeister, F. B., McLaughlin, P. J., Rodriguez, M. A., Kwak, L. W., Zhou, Y., Kantarjian, H. M., & Romaguera, J. E. (2008) · Cancer · doi:10.1002/cncr.23880 · Cited by 33
Self-citationTuomi, J. M., Xenocostas, A., & Jones, D. L. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.001 · Cited by 32
Holte, H., Beiske, K., Boyle, M., Trøen, G., Blaker, Y. N., Myklebust, J. H., Kvaløy, S., Rosenwald, A., Lingjærde, O. C., Rimsza, L. M., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15518 · Cited by 27
Ibrutinib-associated ventricular arrhythmia in the FDA Adverse Event Reporting System
Cheng, C., Woronow, D. I., Nayernama, A., Wroblewski, T., & Jones, S. C. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1457149 · Cited by 26
Bomben, R., Ferrero, S., D’Agaro, T., Bo, M. D., Re, A., Evangelista, A., Carella, A. M., Zamò, A., Vitolo, U., Omedè, P., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.184325 · Cited by 23
Agarwal, R., Dawson, M. A., Dreyling, M. H., & Tam, C. S. L. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1457148 · Cited by 19
Romaguera, J. E., Wang, M. L., Feng, L., Fayad, L., Hagemeister, F. B., McLaughlin, P. J., Rodriguez, M. A., Fanale, M. A., Orlowski, R. Z., Kwak, L. W., et al. (2018) · Cancer · doi:10.1002/cncr.31361 · Cited by 16
Self-citationFichtner, M. W., Spies, E., Seismann, H., Riecken, K., Engels, N., Gösch, B., Dierlamm, J., Gerull, H., Nollau, P., Klapper, W., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.141929 · Cited by 11
D’Agaro, T., Zucchetto, A., Vit, F., Bittolo, T., Tissino, E., Rossi, F. M., Degan, M., Zaja, F. F., Bulian, P., Bo, M. D., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.212811 · Cited by 9
Cited by
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Mato, A. R., Shah, N. N., Jurczak, W., Cheah, C. Y., Pagel, J. M., Woyach, J. A., Fakhri, B., Eyre, T. A., Lamanna, N., Patel, M. R., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00224-5 · Cited by 466
Self-citationWang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.21.02370 · Cited by 331
Self-citation
Metadata
- Authors
- Jain, P., & Wang, M.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2019-04-19
- Volume
- 94
- Issue
- 6
- Pages
- 710-725
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W2937620616
- Cited by
- 274
- References
- 132
- FWCI
- 23.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.